SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mundy GR 1995 Bone remodeling and its disorders. In: FogelmanI (ed.) Metabolic Bone Disease. Martin Dunitz, London, UK, 2738.
  • 2
    Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O 2005 Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 338: 687693.
  • 3
    Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD 1989 Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res 4: 113118.
  • 4
    Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM 1996 Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect Prev 20: 5256.
  • 5
    Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B 1998 Interleukin-1 in multiple myeloma: Producer cells and their role in the control of IL-6 production. Br J Haematol 103: 11521160.
  • 6
    Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, Waage A 1999 Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14: 256263.
  • 7
    Hofbauer LC, Heufelder AE 2001 Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79: 243253.
  • 8
    Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino AC 2003 Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63: 54385445.
  • 9
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P 2003 Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18: 14041418.
  • 10
    Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK, Diamond P, Tamamura H, Lapidot T, Fujii N, Gronthos S 2005 Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65: 17001709.
  • 11
    Grassi F, Cristino S, Toneguzzi S, Piacentini A, Facchini A, Lisignoli G 2004 CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol 199: 244251.
  • 12
    Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B, Arenzana-Seisdedos F, Thelen M, Bachelerie F 2005 The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J Biol Chem 280: 3576035766.
  • 13
    Durig J, Schmucker U, Duhrsen U 2001 Differential expression of chemokine receptors in B cell malignancies. Leukemia 15: 752756.
  • 14
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P 2002 SDF-1 recruits osteoclast (OC) precursors via inducing MMP 9: A mechanism independent from MMP-9 induction during RANKL-mediated OC differentiation. J Bone Miner Res 17: S1;M244.
  • 15
    Grassi F, Piacentini A, Cristino S, Toneguzzi S, Cavallo C, Facchini A, Lisignoli G 2003 Human osteoclasts express different CXC chemokines depending on cell culture substrate: Molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol 120: 391400.
  • 16
    Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Van de Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K 2006 The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica 91: 605612.
  • 17
    Grogan T, Muller-Hermelink H, Van Camp B, Harris N, Kyle RA 2001 Plasma cell neoplasms: Mature B-cell neoplasms. In: JaffeES, SteinH, VardimanJW (eds.) World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France, 142156.
  • 18
    Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S 2005 Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood 105: 37933801.
  • 19
    Zannettino AC, Rayner JR, Ashman LK, Gonda TJ, Simmons PJ 1996 A powerful new technique for isolating genes encoding cell surface antigens using retroviral expression cloning. J Immunol 156: 611620.
  • 20
    Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, Ivanova A, Ageyeva L, Tourkova V, Balatoni J, Bornmann W, Blasberg R, Gelovani Tjuvajev J 2004 A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 31: 740751.
  • 21
    Thai LM, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A 2006 Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 66: 53635370.
  • 22
    Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N 1998 A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochem Biophys Res Commun 253: 877882.
  • 23
    Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, Yamamoto N, Otaka A, Fujii N 2003 T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550: 7983.
  • 24
    Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 35343540.
  • 25
    Revell PA 1986 Quantitative methods in bone biopsy examination. In: RevellPA (ed.) Pathology of Bone. Springer-Verlag, New York, NY, USA, 86111.
  • 26
    Deng X, He G, Levine A, Cao Y, Mullins C 2008 Adenovirus-mediated expression of TIMP-1 and TIMP-2 in bone inhibits osteolytic degradation by human prostate cancer. Int J Cancer 122: 209218.
  • 27
    Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM 1988 Animal model of human disease. Multiple myeloma. Am J Pathol 132: 593597.
  • 28
    Yaccoby S, Barlogie B, Epstein J 1998 Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 29082913.
  • 29
    Araki K, Sangai T, Miyamoto S, Maeda H, Zhang SC, Nakamura M, Ishii G, Hasebe T, Kusaka H, Akiyama T, Tokuda Y, Nagai K, Minami H, Ochiai A 2006 Inhibition of bone-derived insulin-like growth factors by a ligand-specific antibody suppresses the growth of human multiple myeloma in the human adult bone explanted in NOD/SCID mouse. Int J Cancer 118: 26022608.
  • 30
    Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, Popoviciu L, Wang C, Gordon M, Pang S, Bonavida B, Said J, Berenson JR 2006 LAGlambda-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol 28: 14091417.
  • 31
    Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R, Cher ML 2005 Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166: 11731186.
  • 32
    Ara T, Tokoyoda K, Sugiyama T, Egawa T, Kawabata K, Nagasawa T 2003 Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 19: 257267.
  • 33
    Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T 2000 Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 106: 13311339.
  • 34
    Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY 2005 Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 23: 203209.
  • 35
    Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R 2007 Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer. Clin Biochem 40: 12011208.
  • 36
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S 2001 Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98: 35273533.
  • 37
    Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98: 1158111586.
  • 38
    Pellegrino A, Ria R, Di Pietro G, Cirulli T, Surico G, Pennisi A, Morabito F, Ribatti D, Vacca A 2005 Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 129: 248256.
  • 39
    Libura J, Drukala J, Majka M, Tomescu O, Navenot JM, Kucia M, Marquez L, Peiper SC, Barr FG, Janowska-Wieczorek A, Ratajczak MZ 2002 CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100: 25972606.
  • 40
    Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH 2008 Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 29: 14831492.
  • 41
    Hirbe AC, Rubin J, Uluckan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN 2007 Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci USA 104: 1406214067.
  • 42
    Dallas SL, Garrett IR, Oyajobi BO, Dallas MR, Boyce BF, Bauss F, Radl J, Mundy GR 1999 Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 93: 16971706.
  • 43
    Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OL 1985 Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. Cancer 55: 10301040.
  • 44
    Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR 2003 Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102: 311319.
  • 45
    Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J 2002 Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116: 278290.
  • 46
    Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI 2000 Bisphosphonates—mechanisms of action in multiple myeloma. Acta Oncol 39: 829835.